Description
Product Overview / 商品概要
Doxorubicin Hydrochloride for Injection 50mg “NK” (ドキソルビシン塩酸塩注射用50mg「NK」)
Generic: Doxorubicin Hydrochloride / ドキソルビシン塩酸塩
Therapeutic Category: Antineoplastic Agent / 抗悪性腫瘍剤
Manufactured by: Nippon Kayaku Co., Ltd. / 日本化薬株式会社
Composition & Specification / 組成・規格
Active Ingredient: Doxorubicin Hydrochloride 50mg (potency) per vial / 1バイアル中 ドキソルビシン塩酸塩 50mg(力価)
Additives: Lactose hydrate 500mg, Methyl parahydroxybenzoate 5mg, pH adjuster q.s. / 乳糖水和物 500mg、パラオキシ安息香酸メチル 5mg、pH調節剤 適量
Appearance: Red-orange powder or mass; pH 5.0–6.0 (5mg (potency)/mL); osmotic pressure ratio (relative to physiological saline) approx. 1 (10mg (potency)/mL: dissolved in water for injection)
外観: 赤橙色の粉末又は塊、pH 5.0〜6.0(5mg(力価)/mL)、浸透圧比(生理食塩液に対する比)約1(10mg(力価)/mL:注射用水で溶解)
Indications / 効能効果
EN: Doxorubicin Hydrochloride Standard Therapy: Palliation of subjective and objective symptoms of the following conditions: malignant lymphoma, lung cancer, gastrointestinal cancers (gastric cancer, gallbladder/bile duct cancer, pancreatic cancer, hepatic cancer, colon cancer, rectal cancer, etc.), breast cancer, bladder tumor, osteosarcoma. Combination chemotherapy with other antineoplastic agents for: breast cancer (pre- or post-operative chemotherapy in operable cases), endometrial cancer (post-operative chemotherapy, chemotherapy for metastasis/recurrence), malignant bone and soft tissue tumors, malignant bone tumors, multiple myeloma, pediatric malignant solid tumors (Ewing sarcoma family tumors, rhabdomyosarcoma, neuroblastoma, retinoblastoma, hepatoblastoma, nephroblastoma, etc.). M-VAC therapy: urothelial carcinoma.
JA: ドキソルビシン塩酸塩通常療法:下記諸症の自覚的及び他覚的症状の緩解(悪性リンパ腫、肺癌、消化器癌(胃癌、胆のう・胆管癌、膵臓癌、肝癌、結腸癌、直腸癌等)、乳癌、膀胱腫瘍、骨肉腫)。以下の悪性腫瘍に対する他の抗悪性腫瘍剤との併用療法(乳癌(手術可能例における術前あるいは術後化学療法)、子宮体癌(術後化学療法、転移・再発時化学療法)、悪性骨・軟部腫瘍、悪性骨腫瘍、多発性骨髄腫、小児悪性固形腫瘍(ユーイング肉腫ファミリー腫瘍、横紋筋肉腫、神経芽腫、網膜芽腫、肝芽腫、腎芽腫等))。M-VAC療法:尿路上皮癌
Dosage and Administration / 用法用量
EN: Doxorubicin Hydrochloride Standard Therapy: Various dosing regimens depending on indication (refer to full prescribing information). Total cumulative dose should not exceed 500mg (potency)/m² (body surface area). M-VAC Therapy (Urothelial Carcinoma): In combination with methotrexate, vinblastine sulfate, and cisplatin, dissolve doxorubicin hydrochloride in Japanese Pharmacopoeia water for injection or physiological saline; administer 30mg (potency)/m² (BSA) intravenously once per dose. Total cumulative dose of doxorubicin hydrochloride should not exceed 500mg (potency)/m².
JA: 〈ドキソルビシン塩酸塩通常療法〉各適応症に応じた投与方法(詳細は添付文書の用法及び用量欄参照)。総投与量はドキソルビシン塩酸塩として500mg(力価)/m²(体表面積)以下とする。〈M-VAC療法〉尿路上皮癌:メトトレキサート、ビンブラスチン硫酸塩及びシスプラチンとの併用において、通常、ドキソルビシン塩酸塩を日局注射用水または日局生理食塩液に溶解し、成人1回30mg(力価)/m²(体表面積)を静脈内に注射する。ドキソルビシン塩酸塩の総投与量は500mg(力価)/m²以下とする。
Contraindications / 禁忌
EN: Patients with cardiac dysfunction or a history thereof (myocardial damage may occur). Patients with a history of serious hypersensitivity to any component of this product.
JA: 心機能異常又はその既往歴のある患者(心筋障害があらわれることがある)。本剤の成分に対し重篤な過敏症の既往歴のある患者。
Regulatory Information / 規制情報
Approval No.: 22200AMX00021
Sales Started: May 2010 / 2010年5月
Classification Code: 874235
Storage: Store at room temperature / 室温保存
Shelf Life: 2 years / 2年
Packaging / 包装
Main Package (for sale): 1 vial / 1バイアル
Other Available Packages (by special order): 1 vial
Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.




Reviews
There are no reviews yet.